MA46036A - Anticorps anti-vegf-a et anti-ang2 et leurs utilisations - Google Patents

Anticorps anti-vegf-a et anti-ang2 et leurs utilisations

Info

Publication number
MA46036A
MA46036A MA046036A MA46036A MA46036A MA 46036 A MA46036 A MA 46036A MA 046036 A MA046036 A MA 046036A MA 46036 A MA46036 A MA 46036A MA 46036 A MA46036 A MA 46036A
Authority
MA
Morocco
Prior art keywords
vegf
ang2 antibodies
ang2
antibodies
Prior art date
Application number
MA046036A
Other languages
English (en)
Inventor
Mario A Cepeda
Karen Coffman
Nazzareno Dimasi
Ryan Fleming
Changshou Gao
Ching Ching Leow
Mittelman Adrian Schwartz
Ping Tsui
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MA46036A publication Critical patent/MA46036A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA046036A 2016-08-23 2017-08-22 Anticorps anti-vegf-a et anti-ang2 et leurs utilisations MA46036A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662378388P 2016-08-23 2016-08-23

Publications (1)

Publication Number Publication Date
MA46036A true MA46036A (fr) 2019-07-03

Family

ID=59714013

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046036A MA46036A (fr) 2016-08-23 2017-08-22 Anticorps anti-vegf-a et anti-ang2 et leurs utilisations

Country Status (9)

Country Link
US (2) US10836819B2 (fr)
EP (1) EP3504237A1 (fr)
JP (1) JP7174691B2 (fr)
KR (1) KR102543878B1 (fr)
CN (1) CN109863171B (fr)
AU (1) AU2017315075B2 (fr)
IL (1) IL264962B2 (fr)
MA (1) MA46036A (fr)
WO (1) WO2018037000A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
JP2023530187A (ja) * 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
CN116323663A (zh) 2020-09-04 2023-06-23 豪夫迈·罗氏有限公司 与vegf-a和ang2结合的抗体及其使用方法
EP4313148A4 (fr) * 2021-03-30 2025-02-19 Abpro Corporation Méthodes de traitement de la néovascularisation choroïdienne à l'aide d'anticorps multi-spécifiques anti-ang2 x vegf
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
US11883030B2 (en) 2022-04-29 2024-01-30 inQB8 Medical Technologies, LLC Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
AU2023262477A1 (en) 2022-04-29 2024-12-05 Relief Cardiovascular, Inc. Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
WO2024085606A1 (fr) * 2022-10-20 2024-04-25 (주)니오테스바이오 Anticorps bispécifique comprenant un premier site de liaison à l'antigène qui se lie de maniere spécifique à l'angiopoïétine-2 humaine et son utilisation
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
WO2001097850A2 (fr) 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinaisons et compositions perturbant la fonction des recepteurs vegf/vegf et angiopoietine/tie et leur utilisation (ii)
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2006068953A2 (fr) * 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations
EP1962903B1 (fr) * 2005-12-15 2013-03-13 MedImmune Limited Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1995309A1 (fr) 2007-05-21 2008-11-26 Vivalis Production de protéine recombinante dans des cellules aviaires EBx
WO2009055343A2 (fr) 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
RU2509085C2 (ru) 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102250248A (zh) * 2011-06-15 2011-11-23 常州亚当生物技术有限公司 抗vegf/ang2双特异性抗体及其应用
EP2776061B1 (fr) * 2011-11-07 2019-08-14 MedImmune, LLC Protéines de liaison multispécifiques et multivalentes et leurs utilisations
EP2872534B1 (fr) * 2012-07-13 2018-08-08 Roche Glycart AG Anticorps bispécifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
SG11201609168PA (en) * 2014-05-07 2016-12-29 Medimmune Llc Methods of using anti-ang2 antibodies
JP2017537896A (ja) * 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2

Also Published As

Publication number Publication date
IL264962B2 (en) 2024-09-01
WO2018037000A1 (fr) 2018-03-01
AU2017315075A1 (en) 2019-04-04
IL264962B1 (en) 2024-05-01
CN109863171A (zh) 2019-06-07
US20210040194A1 (en) 2021-02-11
KR20190039577A (ko) 2019-04-12
JP2019528694A (ja) 2019-10-17
EP3504237A1 (fr) 2019-07-03
AU2017315075B2 (en) 2020-10-01
IL264962A (en) 2019-05-30
CA3034574A1 (fr) 2018-03-01
JP7174691B2 (ja) 2022-11-17
KR102543878B1 (ko) 2023-06-14
US10836819B2 (en) 2020-11-17
US11566068B2 (en) 2023-01-31
CN109863171B (zh) 2023-08-04
US20190194308A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3377102A4 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
MA46036A (fr) Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
EP3362482A4 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations